Orphan drug designation granted to NurOwn for amyotrophic lateral sclerosis (ALS)

BrainStorm was granted orphan drug designation by the FDA for its drug candidate, NurOwn, an autologous adult stem cell product for the treatment of ALS, or Lou Gehrig’s Disease. NurOwn contains adult human mesenchymal stromal cells induced to differentiate into astrocyte-like cells that secrete neurotrophic factors by means of a specific differentiation-inducing culture medium. This differentiation combined with IM or intrathecal delivery makes it especially attractive for treating ALS.

For more information call (212) 557-9000 or visit www.brainstorm-cell.com.